Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
13.71
-0.04 (-0.33%)
Streaming Delayed Price
Updated: 10:14 AM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
261,566
Open
13.91
Bid (Size)
13.71 (100)
Ask (Size)
13.72 (400)
Prev. Close
13.76
Today's Range
13.58 - 13.96
52wk Range
12.25 - 30.98
Shares Outstanding
97,381,774
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Today 7:00 EDT
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst
↗
July 23, 2026
Via
Chartmill
Performance
YTD
-21.7%
-21.7%
1 Month
-13.9%
-13.9%
3 Month
-21.8%
-21.8%
6 Month
-6.0%
-6.0%
1 Year
-53.2%
-53.2%
More News
Read More
Summit Therapeutics Q2 Earnings Call Highlights
↗
July 23, 2026
Via
MarketBeat
Topics
Earnings
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From
Summit Therapeutics
Via
Business Wire
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From
Summit Therapeutics
Via
Business Wire
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 30, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From
Summit Therapeutics
Via
Business Wire
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
↗
May 31, 2026
Via
The Motley Fool
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
May 31, 2026
From
Summit Therapeutics
Via
Business Wire
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026
From
Summit Therapeutics
Via
Business Wire
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
↗
May 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
↗
May 23, 2026
Via
The Motley Fool
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026
From
USA News Group
Via
GlobeNewswire
What's going on in today's session
↗
May 01, 2026
Via
Chartmill
Which stocks are moving on Friday?
↗
May 01, 2026
Via
Chartmill
Summit Therapeutics Stock Dips After Q1 Financial Report
↗
May 01, 2026
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
May 01, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
May 01, 2026
Via
Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
April 30, 2026
Via
Chartmill
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
April 30, 2026
From
Summit Therapeutics
Via
Business Wire
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
March 27, 2026
From
Summit Therapeutics
Via
Business Wire
Frequently Asked Questions
Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 13.71
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 08/05/26 10:14 AM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.34B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today